ENDRA Life Sciences Inc
NASDAQ:NDRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ENDRA Life Sciences Inc
Accounts Payable
ENDRA Life Sciences Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Accounts Payable
$383k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
17%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accounts Payable
$1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Accounts Payable
$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
16%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accounts Payable
$4.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
15%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Accounts Payable
$110.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accounts Payable
$255.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
See Also
What is ENDRA Life Sciences Inc's Accounts Payable?
Accounts Payable
383k
USD
Based on the financial report for Dec 31, 2025, ENDRA Life Sciences Inc's Accounts Payable amounts to 383k USD.
What is ENDRA Life Sciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
17%
Over the last year, the Accounts Payable growth was 42%. The average annual Accounts Payable growth rates for ENDRA Life Sciences Inc have been -14% over the past three years , -1% over the past five years , and 17% over the past ten years .
